MBX
$29.74
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Intraday
Recent News
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus
MBX Biosciences (NasdaqGS:MBX) completed a successful End-of-Phase 2 meeting with the FDA for its lead candidate canvuparatide in chronic hypoparathyroidism. The company secured orphan drug designation for canvuparatide from the European Medicines Agency. MBX announced plans to advance canvuparatide into a pivotal Phase 3 trial. MBX appointed experienced biopharma executive Karen Basbaum as Chief Business Officer, expanding its leadership team. MBX Biosciences focuses on therapies for...
MBX Biosciences CFO Shift Puts Funding And Execution In Focus
MBX Biosciences (NasdaqGS:MBX) announced the resignation of Chief Financial Officer Richard Bartram. The company appointed John Smither as Interim CFO, effective upon Bartram’s departure. Smither brings extensive prior CFO and board experience in the biopharma sector to the interim role. For a company like MBX Biosciences, which is focused on developing therapies in the biopharma space, a change at the CFO level sits at the core of how it manages cash, partnerships, and future funding...
MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway
MBX Biosciences (NASDAQ:MBX) executives outlined key clinical and development milestones expected through 2026 during an Oppenheimer life sciences team event featuring CEO Kent Hawryluk and Chief Medical Officer Samer Ali. The company highlighted three clinical-stage programs, ongoing obesity-focuse
TripAdvisor, Orthofix Medical, and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return
MBX Biosciences (MBX) has drawn attention after posting a total return of about 261% over the past year, with recent gains in the month and past 3 months prompting closer scrutiny of its clinical pipeline and cash burn. See our latest analysis for MBX Biosciences. The recent move in MBX Biosciences' share price to $42.39, alongside a 31.65% 1 month share price return and 149.35% 3 month share price return, fits into a year where the 1 year total shareholder return of 261.38% points to strong...